Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Introduction

It is clear that SARS-CoV-2 caught the world by surprise. In large part due to globalization, the virus quickly evolved from a serious regional concern to a worldwide pandemic, the likes of which are unprecedented in the last century. In a matter of weeks, COVID-19 became a leading cause of death in 2020, with a staggering potential death toll. Due to a heavy burden of illness, and in the absence of proven therapies, several experimental treatments have been, and continue to be, prescribed outside of clinical trial settings. Of the potential therapeutic options that showed early promise, few have generated as much controversy, or been subject to such politicization, as hydroxychloroquine. In this issue of the International Journal of Infectious Diseases, Arshad et al. (2020) have heightened the controversy.

The authors conducted a retrospective cohort study of 2541 consecutive patients admitted to their health system in Michigan, USA. Patients were separated into four groups: no treatment (n = 409), azithromycin alone (n = 147), hydroxychloroquine alone (n = 1202), and hydroxychloroquine plus azithromycin (n = 783). The primary outcome was mortality. Using a multivariable Cox regression model they adjusted for a number of demographics (e.g. age and sex), comorbidities (e.g. cardiovascular disease and BMI), as well as some markers of disease severity on admission (e.g. oxygen saturation). The mSOFA score was missing in 25% of participants, and so while it was present in the demographics, it was not included in the final model. The authors’ analysis suggested that hydroxychloroquine, with or without azithromycin, was associated with a reduced hazard ratio for death when compared with receipt of neither medication. Using a propensity score matched analysis, with the same variables, they reached a similar conclusion.

Strengths and weaknesses

The main strength of this retrospective cohort study was the inclusion of consecutive patients with laboratory-confirmed COVID-19 from a large healthcare system that included a representative population of socially vulnerable, ethnically diverse individuals. Statistical methods included efforts to adjust for possible confounders through multivariable Cox regression and via propensity score matching.

The limitations of this study are important to consider. First, the precision of the results was impacted by immortal time bias, because several time-dependent covariates were not modelled in this manner. Fortunately, since the average time to receipt of treatment was only 1 day, this bias may be small; nonetheless, it favored treatment and so should be taken into consideration.

Second, there was an important potential for residual confounding because of a number of prognostic factors (e.g. frailty, residence in long term care, or ‘do not resuscitate’ orders), potentially important markers of disease severity (e.g. ferritin, C-reactive protein (Zeng et al., 2020), troponins (Vrsalovic and Vrsalovic Presecki, 2020), and D-dimer (Zhang et al., 2020)), and co-administration of potentially beneficial therapies (e.g. anticoagulants (Paranjpe et al., 2020)) that were not included in the analysis.

Third, confounding by severity or indication (Kyriacou and Lewis, 2016) was likely. While there was a hospital treatment protocol in place, unmeasured clinical factors likely influenced the decision not to treat 16.1% of patients, in a center where 78% received treatment. These factors are often difficult to capture in an observational study. Were the decision to withhold treatment related to poor prognosis (e.g. palliative intent), it stands to reason that patients receiving neither hydroxychloroquine nor azithromycin would have the highest mortality. Indeed, the non-treated group had an overall mortality that was higher than the rate of admission to the ICU (26.4% vs 15.2%), suggesting that many patients were not considered appropriate for critical care. Such being the case, their care may have differed in other substantive ways that were also associated with death (e.g. terminal illness or advanced directives limiting invasive care). In the hydroxychloroquine treatment groups, the inverse was true, with mortality lower than the rate of admission to the ICU (16.1% vs 26.9%). While a propensity score analysis might further account for some differences between treatment groups, this approach was still limited to the information available in the dataset.

Fourth, the chronological time point over the course of the pandemic at which patients were managed was not included in the study. As the Henry Ford Health System became more experienced in treating patients with COVID-19, survival may have improved, regardless of the use of specific therapies. Hospital-specific guidelines regarding COVID-19 screening eligibility as well as...

http://dx.doi.org/10.1016/j.ijid.2020.06.095
1201-9712/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the availability of COVID-19 testing may have also changed over time, introducing additional chronological bias.

Finally, concomitant steroid use in patients receiving hydroxychloroquine was more than double the non-treated group. This is relevant if we consider the recent RECOVERY trial, which showed a mortality benefit with dexamethasone (Horby et al., 2020) among individuals requiring supplemental oxygen or mechanical ventilation, potentially biasing this study’s results in favor of hydroxychloroquine.

Implications

In a global context, this study is thought-provoking, with results that contradict those from other large US cohorts (Geleris et al., 2020; Rosenberg et al., 2020). It remains fundamentally limited by its observational nature and is subject to residual confounding. The published results of the UK RECOVERY and WHO Solidarity trials are not available at the time of writing, but both studies are expected to conclude that hydroxychloroquine does not decrease mortality in hospitalized COVID–19 patients when compared with standard of care (RECOVERY, 2020; World Health Organization, 2020). Given the current polarized opinions surrounding hydroxychloroquine, there will likely be energetic discussion following their eventual publication.

Overall, the authors should be commended for rapidly compiling and analyzing data from a large cohort of COVID–19 patients. Clinicians worldwide should be acknowledged for their best efforts in caring for patients in uncertain times and in the absence of proven therapies. It is, however, very sobering to note that the number of patients in this single observational study would have made a substantive contribution to any randomized controlled trial. While all healthcare providers feel a clinical imperative to offer patients treatment, there was little evidence to justify a hydroxychloroquine protocol at the outset of the pandemic. It is a failing of healthcare systems and the research infrastructure that the protocolization of unproven therapies is exponentially easier to execute than participation in pragmatic randomized controlled trials. Moving forward, we encourage academic centers to commit to participating in the necessary clinical trials that will establish high-quality evidence for safe and effective therapies in the shortest possible time.

Contributions

All authors contributed equally to this editorial, and are listed in alphabetical order. The initial draft was written by TCL and then jointly revised by all co-authors.

Acknowledgements

Drs Lee and McDonald receive research salary support from the Fonds de Recherche Québec – Santé. Dr Tong is an Australian National Health and Medical Research Council Career Development Fellow (#1145033).

References

Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang D, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID–19. Int J Infect Dis 2020;97:396–403, doi:http://dx.doi.org/10.1016/j.ijid.2020.06.099 In this issue.

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripsecak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid–19. N Engl J Med 2020;382(25):2411–8.

Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID–19 — preliminary report. N Engl J Med 2020; doi:http://dx.doi.org/10.1056/ NEJMo2021436 In press.

Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. J Am Med Assoc 2016;316(17):1818–9.

Paranjpe I, Fuster V, Lala A, Russak A, Clinksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID–19. J Am Coll Cardiol 2020;.

RECOVERY. No Clinical benefit from use of Hydroxychloroquine in Hospitalised Patients with COVID–19. 2020 Available from: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid–19-therapy-recovery- UK-and-solidarity-clinical-trial-for-covid–19-treatments. [Accessed 8 June 2020].

Rosenberg ES, Dufort EM, Udo T, Wilberschied IA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID–19 in New York State. J Am Med Assoc 2020;323(24):2493–502.

Vrsalovic M, Vrsalovic Preseki A. Cardiac troponins predict mortality in patients with COVID–19: a meta-analysis of adjusted risk estimates. J Infect 2020; S0163-4453(20)30300-30305.

World Health Organization. Solidarity* Clinical Trial for COVID–19 Treatments - update on Hydroxychloroquine. 2020 Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid–19-treatments. [Accessed 21 June 2020].

Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID–19: a meta-analysis. Int J Infect Dis 2020;96:467–74.

Zhang Y, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid–19. J Thromb Haemost 2020;18 (6):1324–9.

Todd C. Lee a,b,c,*

aClinical Practice Assessment Unit, Department of Medicine, McGill University, Montréal, Canada

bDivision of General Internal Medicine, Department of Medicine, McGill University, Montréal, Canada

cDivision of Infectious Diseases, Department of Medicine, McGill University, Montréal, Canada

Lauren J. MacKenzie a,b

aSection of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, Canada

bDepartment of Community Health Sciences, University of Manitoba, Winnipeg, Canada

Emily C. McDonald a,b

aClinical Practice Assessment Unit, Department of Medicine, McGill University, Montréal, Canada

bDivision of General Internal Medicine, Department of Medicine, McGill University, Montréal, Canada

Steven Y.C. Tong

Victorian Infectious Diseases Service, The Royal Melbourne Hospital, and Doherty Department University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia

* Corresponding author at: Royal Victoria Hospital, 1001 Decarie Blvd Room E5.1820, Montréal, H4A3J1 QC Canada. E-mail address: todd.lee@mcgill.ca (T. Lee).

Received 28 June 2020